Skip to main content
. 2018 Mar 1;14:453–459. doi: 10.2147/TCRM.S156350

Figure 2.

Figure 2

Percent changes of bone metabolic markers and bone mineral density for 18 months after denosumab therapy.

Notes: Percent changes in serum BAP (A) and serum TRACP-5b (B) for the 18-month study period. Percent changes in L-BMD (C) and H-BMD (D) for the 18-month study period. Circles show the TNF group, triangles show the TCZ group, and rectangles show the ABT group. *p<0.05 and **p<0.01 denote significant differences compared with pretreatment in the TNF, TCZ, or ABT groups. ##p<0.01 shows significant differences between the groups at each time point.

Abbreviations: ABT, abatacept; BAP, bone-specific alkaline phosphatase; BMD, bone mineral density; H-BMD, hip bone mineral density; L-BMD, lumbar bone mineral density; TCZ, tocilizumab; TNF, tumor necrosis factor inhibitors; TRACP-5b, tartrate-resistant acid phosphatase 5b.